Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
How does Barringtonia racemosa work to reduce fever?
Barringtonia racemosa contains bioactive compounds including saponins, lupeol, flavonoids, and phenolics that contribute to its antipyretic and anti-inflammatory properties. These compounds are believed to inhibit inflammatory mediators and reduce prostaglandin synthesis, which helps lower elevated body temperature during fever. The plant's traditional use for fever treatment spans Malay, Indian, and Pacific medicine systems. Evidence level C indicates support from limited clinical studies and substantial traditional use, though the exact molecular mechanisms require further investigation through controlled research.
Is Barringtonia racemosa safe during pregnancy?
Barringtonia racemosa is considered unsafe during pregnancy and should be avoided entirely. The plant contains saponins that can cause toxicity and may potentially stimulate uterine contractions, posing risks to fetal development. Traditional medicine systems across Malaysia, India, and the Pacific Islands have historically contraindicated internal use in pregnant women. There is insufficient safety data for breastfeeding women as well. Women who are pregnant, planning pregnancy, or breastfeeding should not use this herb in any form without explicit guidance from a qualified healthcare provider.
What is the recommended dosage for Barringtonia racemosa?
The traditional adult dosage for Barringtonia racemosa is 5-10 grams of bark or leaf prepared as a decoction, taken once or twice daily. To prepare, boil the plant material in water for 15-20 minutes, then strain before consumption. Users should not exceed this recommended range, as higher doses may cause saponin toxicity and gastrointestinal upset. Evidence level C indicates this dosing is based on traditional use rather than standardized clinical trials. Starting with lower doses and adjusting based on individual tolerance is advisable.
Does Barringtonia racemosa interact with any medications?
There are no well-documented drug interactions for Barringtonia racemosa in current medical literature. However, due to its saponin content, theoretical interactions may exist with antipyretic medications, anti-inflammatory drugs, and agents affecting gastrointestinal function. Saponins can potentially enhance drug absorption or cause additive effects. Patients taking prescription medications should consult a qualified healthcare provider before using Barringtonia racemosa. Evidence level C applies to interaction data, meaning recommendations are based on theoretical concerns and traditional knowledge rather than formal interaction studies.
What are the side effects of taking Barringtonia racemosa?
The primary side effects of Barringtonia racemosa are gastrointestinal in nature, including nausea, vomiting, and stomach upset, particularly when consumed in high doses. These effects are attributed to the saponin content, which can irritate the digestive tract lining. Internal use of high doses is specifically contraindicated due to potential saponin toxicity. Users should discontinue use if gastrointestinal symptoms develop and seek medical attention if symptoms persist. Evidence level C indicates side effect data comes from traditional use reports and limited clinical observation rather than systematic safety studies.
Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 30 articles PubMed · modèle : gemma4:31b
Résumé
Barringtonia racemosa is a semi-mangrove plant with documented antioxidant, anti-inflammatory, and wound-healing properties [PMID: 24176317, 28053892, 35356313].
Contexte
Barringtonia racemosa (L.) Spreng is an allotetraploid semi-mangrove plant belonging to the Lecythidaceae family [PMID: 38157253, 38464614]. It is found in regions such as Mainland China and South Africa, where it exhibits high tolerance to salt and heavy metals like lead and cadmium [PMID: 36232247, 38464614, 39732794].
Usages traditionnels
In Ayurveda (Indian medicine), the fruits are believed to be useful in cancer treatment [PMID: 27877231] and for the treatment of pain and inflammatory conditions [PMID: 28053892]. The fruits have also been used as traditional remedies for abscess, ulcer, cough, asthma, and diarrhea [PMID: 26941539]. It is used in the traditional medicine of Sri Lanka [PMID: 12686437].
Composés actifs
The plant contains various polyphenols, including gallic acid, ellagic acid, quercetin, protocatechuic acid, rutin, and kaempferol [PMID: 24176317, 26839752]. Other identified compounds include bartogenic acid (a pentacyclic triterpenoid) [PMID: 17059003, 27877231], acylated flavonoid glycosides (barringosides G-I) [PMID: 30676065], ellagitannins (barringtins and barricyclin D1) [PMID: 33890626], and various oleanane-type triterpenoids such as racemosol A and isoracemosol A [PMID: 19388709, 27498717].
Mécanisme d'action
Barringoside I inhibits LPS-induced NO production in RAW264.7 cells [PMID: 30676065]. Bartogenic acid demonstrates cytotoxicity against SCC-13 skin carcinoma cells [PMID: 27877231] and suppresses NF-κB in ovarian cancer tumors [PMID: 34255109]. Leaf water extracts (BLE) inhibit Caco-2 cells by up-regulating SLC2A1 and down-regulating ADH4 [PMID: 32561807]. Aqueous bark extracts exhibit antinociceptive effects mediated primarily via opioid mechanisms [PMID: 12686437].
Preuves cliniques
Preuve DWound Healing
Topical application of a gel formulation containing B. racemosa kernel extract accelerated the wound healing process in rat models [PMID: 35356313].
Preuve DInflammation
An ethyl acetate fraction of the fruits (BREAF) showed dose-dependent anti-inflammatory activity in both acute (rat paw edema) and chronic (cotton pellet granuloma) animal models [PMID: 28053892].
Preuve DSkin Carcinogenesis
Bartogenic acid (BA) reduced the development of DMBA/Croton oil-induced skin carcinogenesis in mice when administered orally or topically [PMID: 27877231].
Preuve DOvarian Cancer
Bartogenic acid alone and in combination with paclitaxel significantly suppressed tumor growth in SKOV-3 xenografted SCID mice [PMID: 34255109].
Preuve DPain (Nociception)
Aqueous bark extract showed antinociceptive activity in hot plate and formalin tests in rats [PMID: 12686437].
Sécurité et effets indésirables
Aqueous bark extract was reported as non-toxic and non-teratogenic in rats [PMID: 12686437]. However, intravenous administration of bartogenic acid (BA) in mice showed mortality at a single dose of 100 mg/kg and significant reduction in body weight at repeated doses of 24 mg/kg [PMID: 36504921].
Grossesse et allaitement
Aqueous bark extract did not alter fertility, gestational length, or peri- and neonatal development in rats [PMID: 12686437].
Synthèse des preuves
The current evidence is based on in vitro cell studies and in vivo animal models (Level D). There are no human clinical trials (RCTs) or systematic reviews provided.
Sources PubMed
1.PMID: 30676065 (2020) — Acylated flavonoid glycosides from Barringtonia racemosa. · Natural product research
2.PMID: 28905569 (2016) — [Chemical constituents from Barringtonia racemosa]. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
3.PMID: 36232247 (2022) — New Evidence of Semi-Mangrove Plant Barringtonia racemosa in Soil Clean-Up: Tolerance and Absorption of Lead and Cadmium. · International journal of environmental research and public health
4.PMID: 39732794 (2024) — Interspecific competition and survival pressures in endangered Barringtonia racemosa populations of Mainland China. · Scientific reports
5.PMID: 38464614 (2024) — Mechanism of salt tolerance in the endangered semi-mangrove plant Barringtonia racemosa: anatomical structure and photosynthetic and fluorescence characteristics.
Sources gouvernementales
Aucune monographie gouvernementale directe n'est disponible pour cette plante. Le contenu ci-dessous est généré par IA et n'a pas été vérifié par rapport à une source gouvernementale faisant autorité. Utilisez les liens de recherche pour consulter les sources officielles avant de vous fier à ces informations.
6.PMID: 24176317 (2014) — Polyphenols in Barringtonia racemosa and their protection against oxidation of LDL, serum and haemoglobin. · Food chemistry
7.PMID: 35356313 (2022) — Acceleration of wound healing by topical application of gel formulation of Barringtonia racemosa (L.) Spreng kernel extract. · F1000Research
8.PMID: 19388709 (2009) — Oleanane-type isomeric triterpenoids from Barringtonia racemosa. · Journal of natural products
9.PMID: 38157253 (2024) — The evolution history of an allotetraploid mangrove tree analysed with a new tool Allo4D. · Plant biotechnology journal
11.PMID: 27877231 (2016) — Chemomodulatory Potential of Bartogenic Acid Against DMBA/Croton Oil Induced Two-Step Skin Carcinogenesis in Mice. · Journal of Cancer
12.PMID: 34190667 (2021) — Anti-inflammatory effect of Barringtonia angusta methanol extract is mediated by targeting of Src in the NF-κB signalling pathway. · Pharmaceutical biology
13.PMID: 32561807 (2020) — Evaluation of Anti-proliferative Effects of Barringtonia racemosa and Gallic Acid on Caco-2 Cells. · Scientific reports
14.PMID: 24575198 (2010) — Toxicity of Barringtonia racemosa (L.) Kernel Extract on Pomacea canaliculata (Ampullariidae). · Tropical life sciences research
15.PMID: 26839752 (2016) — Protective effects of the extracts of Barringtonia racemosa shoots against oxidative damage in HepG2 cells. · PeerJ
16.PMID: 33890626 (2021) — Barricyclin D1-a dimeric ellagitannin with a macrocyclic structure-and accompanying tannins from Barringtonia racemosa. · Bioscience, biotechnology, and biochemistry
17.PMID: 27635343 (2016) — Antioxidant-rich leaf extract of Barringtonia racemosa significantly alters the in vitro expression of genes encoding enzymes that are involved in methylglyoxal degradation III. · PeerJ
18.PMID: 26941539 (2016) — Antioxidant and Cytotoxic Effect of Barringtonia racemosa and Hibiscus sabdariffa Fruit Extracts in MCF-7 Human Breast Cancer Cell Line. · Pharmacognosy research
19.PMID: 17059003 (2006) — [Chemical constituents of mangrove plant Barringtonia racemosa]. · Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials
20.PMID: 26697277 (2015) — Development of EST-SSR markers in Barringtonia racemosa (Lecythidaceae) and cross-amplification in related species. · Applications in plant sciences
21.PMID: 35583452 (2022) — Streptomyces barringtoniae sp. nov., isolated from rhizosphere of plant with antioxidative potential. · International journal of systematic and evolutionary microbiology
22.PMID: 28053892 (2017) — Anti-inflammatory activity of bartogenic acid containing fraction of fruits of Barringtonia racemosa Roxb. in acute and chronic animal models of inflammation. · Journal of traditional and complementary medicine
23.PMID: 27562287 (2016) — Ophiostomatoid fungi associated with mangroves in South Africa, including Ophiostoma palustre sp. nov. · Antonie van Leeuwenhoek
24.PMID: 27498717 (2017) — Self gelating isoracemosol A, new racemosaceramide A, and racemosol E from Barringtonia racemosa. · Natural product research
25.PMID: 36504921 (2022) — Single and repeated dose (28 days) intravenous toxicity assessment of bartogenic acid (an active pentacyclic triterpenoid) isolated from Barringtonia racemosa (L.) fruits in mice. · Current research in toxicology
26.PMID: 12686437 (2003) — Antinociceptive effect and toxicological study of the aqueous bark extract of Barringtonia racemosa on rats. · Journal of ethnopharmacology
27.PMID: 16649558 (2006) — Two new 18-en-oleane derivatives from marine mangrove plant, Barringtonia racemosa. · Die Pharmazie
28.PMID: 28317540 (2017) — Endophytic Botryosphaeriaceae, including five new species, associated with mangrove trees in South Africa. · Fungal biology
29.PMID: 34255109 (2021) — Tumor-suppressing effect of bartogenic acid in ovarian (SKOV-3) xenograft mouse model. · Naunyn-Schmiedeberg's archives of pharmacology